Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839129 | 0.83 | HSD17B10 (0.51) | HSD17B10GABRA5GABRB2ALDH1A1KDM4E | |
| SCHEMBL12801753 | 0.83 | HSD17B10 (0.51) | HSD17B10GABRA5GABRB2ALDH1A1KDM4E | |
| SCHEMBL12548427 | 0.82 | HSD17B10 (0.54) | HSD17B10GABRA5GABRB2ALDH1A1KDM4E | |
| SCHEMBL11130654 | 0.81 | HSD17B10 (0.62) | HSD17B10GABRA5GABRB2ALDH1A1KDM4E | |
| SCHEMBL1614004 | 0.81 | ALDH1A1 (0.39) | HSD17B10GABRA5GABRB2ALDH1A1MAPT | |
| SCHEMBL16603280 | 0.81 | ALDH1A1 (0.39) | HSD17B10GABRA5GABRB2ALDH1A1LMNA | |
| SCHEMBL5034313 | 0.81 | ALDH1A1 (0.39) | HSD17B10GABRA5GABRB2ALDH1A1MAPT | |
| SCHEMBL18971953 | 0.81 | HSD17B10 (0.53) | HSD17B10GABRA5GABRB2ALDH1A1KDM4E | |
| SCHEMBL20662506 | 0.80 | HSD17B10 (0.51) | HSD17B10GABRA5GABRB2ALDH1A1KDM4E | |
| SCHEMBL855213 | 0.79 | SMN1; SMN2 (0.57) | ALDH1A1KDM4EHPGDLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| CN-102803237-B | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2014-09-24 | — | — | CN | disclosed |
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| CN-102803237-A | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | HSD17B10 518/4885GABRA5 3532/4885GABRB2 3332/4885 |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | HSD17B10 1552/4885GABRA5 102/4885GABRB2 237/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | HSD17B10 394/4885GABRA5 3791/4885GABRB2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.